Hadassah Medical CenterHadassah Medical Center
   Home    About    International Patient    Contact 
Home > Physicians, Dentists, Investigators

Dr. Shoshana Revel-Vilk

 

 

 

Pediatric Hematology-Oncology Unit

Department of Hematology

Hadassah University Hospital

Ein-Karem, Jerusalem

E-mail:  revelvilk@hotmail.com

 

 

Born: 9.12.1966    

Home Address: 2 Miriam Hashmonait st.. Jerusalem 93558. Israel

 

Professional education

 

1986-1992  M.D. degree, Hebrew university-Hadassah medical school, Jerusalem, Israel

 

Professional experience

 

1993 Rotating internship, Bikur-Cholim Hospital, Jerusalem, affiliated with the Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

1994-1998 Pediatric residency, Bikur-Cholim Hospital, Jerusalem, affiliated with the Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

1997 Basic science residency, Department of Bone-Marrow-Transplant, Hadassah Hospital, Ein-Karem, Jerusalem, Israel

 

1999-2001 Clinical fellowship, Department of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Canada

 

2001-2002 Clinical/research fellowship in Pediatric Thrombosis and Hemostasis, Department of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Canada

 

2002 - Staff, Pediatric Hematology/Oncology Unit, Hadassah Medical Center, Hebrew University, Jerusalem, Israel

 

Teaching experience

 

1994-1998 Involved with teaching of medical students, Department of Pediatrics, Bikur- Cholim Hospital, affiliated with the Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

1999–2001 Involved with teaching of medical students, Department of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Canada

 

2002 - Involved with teaching of medical students. Department of Pediatrics, Hadassah Medical Center, Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

Academic appointments

 

1998-1999 Clinical teaching assistant, Department of Pediatrics, Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

2002 - Clinical teaching assistant, Department of Pediatrics, Hebrew University-Hadassah Medical School, Jerusalem, Israel

 

Awards/Grants

 

Louis Weingarden prize of excellence for the M.D. Thesis, entitled: “Immunological parameters following a clinical trial of ambulatory cytokine mediated immunotherapy of recombinant Interferon alfa and Interleukin 2”. American Physicians Fellowship for medicine in Israel (APF) , Pearl Foundation Grant for Fellowship, Israel

 

2001  Research training competition (Restracomp) award, The Hospital for Sick Children, University of Toronto, Canada for a research project entitled: “Pilot study: Low molecular weight heparin (LMWH) in association with low dose chemotherapy as an anti-angiogenesis agent in pediatric patients with refractory solid tumors”

 

2001 Baxter Bioscience Pediatric Hemostasis Fellowship, The Hospital for Sick Children, Toronto, Canada.

 

2001 The Canadian Hematology Society, 2001 Wyeth –Ayerst Travel Award for travel to ASH 2001 for presentation of an abstract entitled: “Incidence of congenital prothrombotic disorders in children with venous thromboembolic disease: A prospective cohort study”

 

2002  The American Society of Pediatric Hematology/Oncology, 2002 Young Investigator Award for an abstract entitled:  “Desmopressin (DDAVP) responsiveness in children with von Willebrand Disease”

 

Continuing Medical Education

 

2001 Workshop, Methods in Clinical Cancer Research, AACR, ASCO, July 28- Aug 3, Vial, Colorado, USA

 

Invited lectures

 

1. Intracranial hemorrhage in children with hemophilia. Hematology/Oncology Rounds, The Hospital for Sick Children, University of Toronto, Toronto, Canada, December 2002

 

2. Impact of intracranial bleeds on the health and quality of life of boys with hemophilia. XIVth Annual Hemophilia Research Study Update, Miami, Florida, January 2004

 

Publications

 

Original reports:

 

1. Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Shahar MB, Slavin S. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-a2a and interleukin-2. Cancer Immunol Immunother 35:401-411, 1992.

 

2. Seidman DS, Ergaz Z, Paz I, Laor A, Revel-Vilk S, Stevenson DK, Gale R. Predicting the risk of jaundice in full-term healthy newborns: a prospective population-based study.  J Perinatol 19:564-7, 1999.

 

3. Revel-Vilk S, Tamary H, Broide E, Zoldan M, Dinari G, Zahavi I, Yaniv I, Shamir R. Serum transferrin receptor in children and adolescents with inflammatory bowel disease.  Eur J Pediatr 159:585-9, 2000.

 

4. Klar A, Gross-Kieselstein E, Shazberg G, Israeli T, Revel-Vilk S, Hurvitz H. Hepatitis A associated with other focal infections. Isr Med Assoc J 2:598-600, 2000.

 

5. Shazberg G, Revel-Vilk S, Shoseyov D, Ben-Ami A, Klar A, Hurvitz H. The clinical course of bronchiolitis associated with acute otitis media. Arch Dis Child 83:317-9, 2000.

 

6. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 117:947-51, 2002.  

 

7. Revel-Vilk, S, Massicotte, P. Thromboembolic diseases of childhood. Blood Rev 17:1-6, 2003.

 

8. Schenk B, Imbach T, Frank CG, Grubenmann CE, Raymond GV, Hurvitz H, Korn-Lubetzki I, Revel-Vilk S, Raas-Rotschild A, Luder AS, Jaeken J, Berger EG, Matthijs G, Hennet T, Aebi M. MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest 111:925, 2003 (corrigendum for original citation J Clin Invest 108:1687-95, 2001).

 

9. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic disorders in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 1:915-921, 2003.

 

10. Revel-Vilk S, Chan AKC. Anticoagulation therapy in children Semin Thromb Hemost 29:425-432, 2003.

 

11. Klar A, Shoseyov D, Berkun Y, Brand A, Braun J, Shazberg G, Moise J, Gross-Kieselstein E, Revel-Vilk S, Hurvitz H. Intestinal permeability defect, clevated fecal a1 antitrypsin excretion and hypoalbuminemia in children with pneumonia.  J Pediatr Gastroenterol Nutr 37:120-3, 2003.

 

12. Revel-Vilk S, Schmugge M, Mannuel C, Blanchette P, Rand M, Blanchette V. Desmopressin (DDAVP) responsiveness in children with von Willebrand Disease. J Pediatr Hematol Oncol 25:874-9, 2003. 

 

13. Schmugge M, Revel-Vilk S, Hiraki L, Rand M, Blanchette V, Silverman E. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus.  J Pediatr 143:666-9, 2003.

 

14. Revel-Vilk, S, Sharathkumar A, Massicotte P, Dix, D, Marzinotto, V, Chan, A.Follow-up history of arterial and venous thrombosis in children treated with Low Molecular Weight Heparin. A longitudinal study by Doppler ultrasound. J Thromb Haemost 2:42-6, 2004.

 

15. Revel-Vilk S, Golomb M, Achonu C, Stain AM, Armstrong D, Sung L, Logan W, Barnes MA, McNeely M, Blanchette V, Feldman B. Impact of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr 144:490-5, 2004.

 

16. Hedlund-Treutiger I, Revel-Vilk S, Blanchette VS, Curtin JA, Lillicrap D, Rand ML. Reliability and Reproducibility of Classification of Children as "Bleeders" Versus "Non-Bleeders" Using a Questionnaire for Significant Mucocutaneous Bleeding. J Pediatr Hematol Oncol. 26:488-91, 2004.

 

17. Revel-Vilk S, Kenet G. Thrombophilia in children with venous thrombosis. Thromb Res 2004 (in press).

 

More in PubMed

 

Case reports:

 

18. Korn-Lubetzki I, Revel-Vilk S, Steiner I, Shoshan Y, Hurvitz H. Continuous deterioration in subacute sclerosing panencephalitis during treatment with osiprinosine and intrathecal interferon alpha. Neurologic infections and epidemiology 2:163-165, 1997.

 

17. Revel-Vilk S, Hurvitz H, Klar A, Virozov Y, Korn-Lubetzki I. Recurrent acute disseminated encephalomyelitis associated with acute cytomegalovirus and Epstein-Barr virus infection. J Child Neurol 15:421-4, 2000.

 

18. Shayan K, Ye C, Revel-Vilk S. Pathologic Quiz Case: 6-Year-Old Girl with Thrombocytopenia. Arch Patho Lab Med 127:e305-6, 2003.

 

19. Weintraub M, Bloom AI, Gross E, Revel-Vilk S, Shahroor S, Koplewitz BZ, Freeman AI. Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization. Pediatr Blood Cancer 43:148-51, 2004.

 

Abstracts:

 

1. Morecki S, Vilk S, Nabet C, Pick M, Nagler A, Ackerstein A, Naparstek E, Ben-Shahar MB, Slavin S.  Immune evaluation of recombinant human alpha-2a Interferon (IFNa) and Interleukin-2 (rIL2) in ambulatory treatment.  Cytokine 3:492, 1991.

 

2. Seidman DS, Ergaz Z, Revel-Vilk S, Paz I, Stark M, Stevenson DK, Gale R. The use of bilirubin measurements on the first day of life for prediction of neonatal jaundice. Program and abstracts of the Ross Special Conference, Hot topics '96 in Neonatology Washington, DC, 1996, pp 284-294.

 

3. Seidman DS, Ergaz Z, Paz I, Revel-Vilk S, Weinberg A, Armon Y, Verman HY, Stevenson DK, Gale R. Can bilirubin levels at age £ 24 hours predict the risk of neonatal jaundice?  Pediatr Res 39:244A, 1996.

 

4. Revel-Vilk S, Doyle JJ, Calderwood S, Saunders FE., Abdolell M, Lau W, Freedman MH. Impaired pre-transplant CD34+ hematopoietic clonogenic activity predicts for recurrent neuroblastoma following autografting. Blood 96:424A, 2000.

 

5. Revel-Vilk S, Blanchette VS, Stain AM, Carcao MD.Interpreting DDAVP challenge tests in mild-moderate hemophilia A. Pediatr Res 49:879A, 2001.

 

6. Revel-Vilk S, Chan A, Knapp C, Koloshuk B, Carsons R, Massicotte P, Andrew M. Incidence of congenital prothrombotic disorders in children with venous thromboembolic disease: A prospective cohort study. Blood 98:50A, 2001.

 

7. Revel-Vilk S, Schmugge M, Mannuel C, Blanchette P, Rand M, Blanchette V. Desmopressin (DDAVP) responsiveness in children with von Willebrand Disease. J Pediatr Hematol Oncol 24:A1, 2002.

 

8. Revel-Vilk S, Schmugge M,. Hiraki L, Blanchette V, Silverman E. Thrombocytopenia in children with Systemic Lupus Erythematosus (SLE). J Pediatr Hematol Oncol 24:A14, 2002.

 

9. Sharathkumar A, Revel-Vilk S, Chan AKC, Marzinotto V, Andrew M, Massicotte P.Outcome of children with thromboembolic events (TEs) treated with low molecular weight heparin (LMWH).  J Pediatr Hematol Oncol 24:A1, 2002.

 

10. Revel-Vilk S, Stain AM, Achonu C, Barnes MA. Impact of intracranial bleeds on the health and quality of life of boys with hemophilia. Hemophilia 8:525 [abstract 09PO26), 2002.

 

11. Revel-Vilk, S, Sharathkumar A, Massicotte P, Dix, D, Marzinotto, V, Chan, A.  Natural history of arterial and venous thrombosis in children treated with Low Molecular Weight Heparin. A longitudinal study by Doppler ultrasound. Blood 100, 279A, 2002.

 

12. Revel-Vilk S, Sharathkumar A, Dix D, Chan AKC, Marzinotto V, Massicotte P.Use of low molecular weight heparin in children with thromboembolic events; predictors for bleeding and recurrence on therapy.  J Thromb Haemost  Suppl 1, P0044, 2003.

 

13. Kenet G, Waldman D, A. Lubetsky, Chalil A, Rosenberg N, Kornbrut N, Koren A, Levin C, Tamary H, Yacobovitch J, Raveh E, Wolach B, Fatal A, Kapelushnik J, Revel-Vilk S, Toren A, Brenner B. Pediatric Cerebral Sinus Vein Thrombosis and Thrombophilia - A Multicenter Study. Blood 102 , 533A, 2003.

 

 

Presentations

 

1. Morecki S, Vilk S, Nabet C, Pick M, Nagler A, Ackerstein A, Naparstek E, Ben-Shahar MB, Slavin S.  Immune evaluation of recombinant human alpha-2a Interferon (IFNa) and Interleukin-2 (rIL2) in ambulatory treatment.  III Int. workshop on cytokines, Stresa, November 1991.

 

2. Seidman DS, Ergaz Z, Revel-Vilk S, Paz I, Stark M, Stevenson DK, Gale R. The use of bilirubin measurements on the first day of life for prediction of neonatal jaundice. The Ross Special Conference, Hot topics '96 in Neonatology Washington, DC.

 

3. Revel-Vilk S, Tamary H, Broida E, Zoldan M, Zahavi I, Dinari G, Yaniv I, Shamir R. Serum tramsferrin receptor in children and adolescents with IBD.  The Israeli Pediatric Gastroenterology Association, Eilat, Israel (In Hebrew), 1999.

 

4. Revel-Vilk S, Doyle JJ, Calderwood S, Saunders FE., Abdolell M, Lau W, Freedman MH. Impaired pre-transplant CD34+ hematopoietic clonogenic activity predicts for recurrent neuroblastoma following autografting. The 42nd Annual meeting, The American Society of Hematology, San Francisco, CA, December 2000.

 

5. Revel-Vilk S., Blanchette V.S., Stain A.M.,. Carcao M.D. Interpreting DDAVP challenge tests in mild-moderate hemophilia A. European Society of Pediatric Hematology and Immunology, Lucern, Switzerland, June 2001.

 

6. Revel-Vilk S, Chan A, Knapp C, Koloshuk B, Carsons R, Massicotte P, Andrew M. Incidence of congenital prothrombotic disorders in children with venous thromboembolic disease: A prospective cohort study. The 43rd Annual meeting, The American Society of Hematology, Orlando, FL, December 2001.

 

7. Revel-Vilk S, Schmugge M, Mannuel C, Blanchette P, Rand M, Blanchette V Desmopressin (DDAVP) responsiveness in children with von Willebrand Disease.. The 15th Annual meeting, The American Society of Pediatric Hematology/Oncology, Baltimore, MD, May 2002.

 

8. Revel-Vilk S, Schmugge M,. Hiraki L, Blanchette V, Silverman E Thrombocytopenia in children with Systemic Lupus Erythematosus (SLE).. The 15th Annual meeting, The American Society of Pediatric Hematology/Oncology, Baltimore, MD, May 2002.

 

9. Sharathkumar A, Revel-Vilk S, Chan AKC, Marzinotto V, Andrew M, Massicotte P.Outcome of children with thromboembolic events (TEs) treated with low molecular weight heparin (LMWH).  The 15th Annual meeting, The American Society of Pediatric Hematology/Oncology, Baltimore, MD, May 2002. J Pediatr Hematol Oncol 24:A1, 2002.

 

10. Revel-Vilk S, Stain AM, Achonu C, Barnes MA. Impact of intracranial bleeds on the health and quality of life of boys with hemophilia. The XXV International Congress of the World Federation of Hemophilia, Seville, Spain, May 2002.

 

11. Revel-Vilk, S, Sharathkumar A, Massicotte P, Dix, D, Marzinotto, V, Chan, A.  Natural history of arterial and venous thrombosis in children treated with Low Molecular Weight Heparin. A longitudinal study by Doppler ultrasound. The American Society of Hematology, Philadelphia, PN, December 2002.

 

12. Revel-Vilk S, Sharathkumar A, Dix D, Chan AKC, Marzinotto V, Massicotte P.  Use of low molecular weight heparin in children with thromboembolic events; predictors for bleeding and recurrence on therapy. The 19th Annual meeting, The International Society of Thrombosis and Haemostasis, Birmingham, UK, July 2003.

 

13. Kenet G, Waldman D, A. Lubetsky, Chalil A, Rosenberg N, Kornbrut N, Koren A, Levin C, Tamary H, Yacobovitch J, Raveh E, Wolach B, Fatal A, Kapelushnik J, Revel-Vilk S, Toren A, Brenner B. Pediatric Cerebral Sinus Vein Thrombosis and Thrombophilia - A Multicenter Study. The American Society of Hematology, San Diego, CA, December 2003.






            
     
 


         Powered by